Zimmer Biomet’s CEO, Ivan Tornos, said the company’s transition to a fully dedicated sales force is going better than expected, leading to raised sales and earnings expectations for 2026. This improved performance is a result of the company’s efforts to restructure its sales force, which was announced in February. The restructuring aims to give Zimmer Biomet a fully dedicated sales force by the end of 2027, allowing the company to better focus on higher growth segments and improve its overall sales performance.
Compared to $152.8 million in Q2 2025, the company’s latest quarterly results show improvement, demonstrating the effectiveness of the restructuring plan. The plan involves shifting its 2,500-person U.S. sales force to fully dedicated specialists, rather than independent contractors, and focusing them on higher growth segments. This change is expected to lead to increased sales and revenue growth for the company.
Tornos told investors that the company is seeing less customer disruption and sales force turnover than initially expected, which is a positive sign for the company’s future performance. They are adding 200 tech sales representatives and has locked in the top six independent distributors, further solidifying the company’s position in the market.
The company raised its revenue growth expectations for the year to a range of 3.9% to 4.9%, from a prior range of 2.5% to 4.5%, indicating a positive outlook for the company’s future performance. Zimmer Biomet also increased its adjusted earnings per share forecast by a few cents, demonstrating the company’s confidence in its ability to deliver strong financial results.
Related: STAAR Surgical names Warren Foust permanent chief executive
According to the report, there’s still some risk ahead, as about half of the sales force restructuring still has yet to be completed. However, J.P. Morgan analyst Robbie Marcus viewed the quarterly results as “incrementally positive,” suggesting that the company is on the right track. With better-than-expected results following softer competitor prints, Marcus thinks these results point to share-taking for Zimmer in 2Q, indicating that the company is gaining ground in the market.
Zimmer’s U.S. knee business grew 1.4% in the quarter, better than Johnson & Johnson‘s 1% growth but below Stryker‘s 6.1% growth. Meanwhile, Zimmer’s U.S. hips segment grew 5.9% in the second quarter, ahead of both of its competitors.
Tornos said the company’s transition to a fully dedicated sales force is a growth strategy, aiming to have the best sales force in orthopedics. By focusing on higher growth segments and building a strong sales force, the company is well-positioned to drive sales growth and increase its market share.
Zimmer Biomet is still on track to complete the restructuring by the end of 2027, with its headquarters in Warsaw, Indiana. The company’s commitment to completing the restructuring plan on schedule is a positive sign, as it demonstrates the company’s focus on delivering strong financial results and driving sales growth.
